Susquehanna Fundamental Investments’s Entasis Therapeutics Holdings Inc. ETTX Stock Holding History

Susquehanna Fundamental Investments’s Portfolio ETTX Stock Details ETTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-21,394	Closed	-$71K	–	1855
2021 Q3	$71K	Sell	21,394 -700	-3%	-$1.9K	﹤0.01%	1644
2021 Q2	$59K	Sell	22,094 -19,783	-47%	-$44.7K	﹤0.01%	1614
2021 Q1	$90K	Buy	41,877 +13,900	+50%	+$39.5K	﹤0.01%	1474
2020 Q4	$69K	Buy	+27,977	New	+$55K	﹤0.01%	1444

Other funds holding ETTX

TGA

TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Janney Montgomery Scott Philadelphia, Pennsylvania $51.6B AUM 27.34% 1-Year Est. Return

Susquehanna Fundamental Investments's ETTX Position: Q4 2021 in Review

Susquehanna Fundamental Investments sold out of Entasis Therapeutics Holdings Inc. (ETTX) in Q4 2021, closing a stake of 21,394 shares — an estimated $71K sold.

Susquehanna Fundamental Investments first reported a position in ETTX in Q4 2020 and held it in 4 quarters. The position peaked at $90K in Q1 2021. 28 funds tracked by Wall St. Rank hold ETTX as of Q4 2021.

Susquehanna Fundamental Investments reported no remaining Entasis Therapeutics Holdings Inc. position as of Q4 2021 after selling out during the quarter.
Susquehanna Fundamental Investments sold 21,394 Entasis Therapeutics Holdings Inc. shares in Q4 2021, an estimated $71K.
Susquehanna Fundamental Investments first reported a position in Entasis Therapeutics Holdings Inc. in Q4 2020 and held it in 4 quarters.
Susquehanna Fundamental Investments's Entasis Therapeutics Holdings Inc. position peaked at $90K in Q1 2021.
28 funds tracked by Wall St. Rank held Entasis Therapeutics Holdings Inc. as of Q4 2021.

Based on Susquehanna Fundamental Investments's 13F filing for Q4 2021, filed 14 Feb 2022.